MES Implementation in Indian Pharma: Pioneering Digital Manufacturing, Overcoming Cost Barriers, and Reducing Process Variability
The pioneer of MES implementation in Indian pharma on why mid-sized companies face cost and product-fit barriers, how to distinguish GMP limits from control limits, and why LIMS, QMS, and MES together cover 90% of compliance needs.
Vivek Gera Host
Co-founder · Leucine
Vilas Dholye
MES Implementation Pioneer · Pharmaceutical Industry
About this episode
Vivek Gera speaks with Vilas Dholye, the person credited with introducing the first MES implementation in an Indian pharmaceutical company — a decision made 15 to 20 years ago when the industry was still entirely paper-based. Vilas describes how he moved from non-pharma to pharma and saw immediately the inefficiency of paper-based GMP documentation, convinced his CEO to invest in best-in-class MES technology at a time when it was considered an innovator-market product, and watched as the company eventually rolled it out to 90% of its plants — proof that the original decision was correct. The episode focuses on why MES adoption has lagged in mid-sized Indian pharma (cost, implementation time, Western products not designed for generic companies) and the practical insight that distinguishing GMP limits from control limits enables significant variability reduction without regulatory change.
Topics
Key takeaways
- The first MES implementation in an Indian pharma company happened 15 to 20 years ago — the company that made that early bet has since rolled it out to 90% of its plants, compounding the first-mover advantage over two decades
- Most standard MES products were designed for innovator companies in the US and Europe — their cost structures and implementation complexity make them inaccessible for mid-sized generic manufacturers, creating a gap that the industry has not yet fully closed
- GMP limits and control limits are not the same: GMP limits define the permissible range for regulatory compliance, but control systems can operate at a much narrower band within that range — reducing variability without requiring regulatory changes or filings
- MES is not optional — the question for most pharma companies is not whether to implement it but when and how; the cost and time of implementation are the real barriers to address, not the business case
- Process improvement in most cases means finding the optimum point within the already-approved GMP range — reducing variability by narrowing the control window, not by fundamentally changing a validated process
- LIMS, QMS, and MES together cover approximately 90% of a pharmaceutical company's compliance and control needs — any system chosen that performs well across these three areas is a sound foundation, regardless of whether it is best-in-class or fit-for-purpose
Continue exploring
Powered by
Leucine MES
See how automated documentation eliminates the gaps that cause FDA 483 observations.
See Leucine MESSee how Leucine's AI-native platform is transforming pharmaceutical quality and manufacturing operations.
